Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
Public ClinicalTrials.gov record NCT03143101. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being conducted to compare the immunogenicity, safety, and viral shedding of a new A/H1N1 strain that will be incorporated into the FluMist quadrivalent formulation for the 2017-2018 influenza season with the previous A/H1N1 strain that was included in the vaccine in the 2015-2016 influenza season.
Study identification
- NCT ID
- NCT03143101
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 200 participants
Conditions and interventions
Interventions
- FluMist trivalent (2015-2016) Biological
- FluMist Quadrivalent (2015-2016) Biological
- FluMist Quadrivalent (2017-2018) Biological
Biological
Eligibility (public fields only)
- Age range
- 24 Months to 47 Months
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 7, 2017
- Primary completion
- Sep 28, 2017
- Completion
- Sep 28, 2017
- Last update posted
- Dec 10, 2018
2017
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Savannah | Georgia | 31405 | — |
| Research Site | Bardstown | Kentucky | 40004 | — |
| Research Site | St Louis | Missouri | 63141 | — |
| Research Site | Norfolk | Nebraska | 68701 | — |
| Research Site | Omaha | Nebraska | 68134 | — |
| Research Site | Binghamton | New York | 13901 | — |
| Research Site | Dakota Dunes | South Dakota | 57049 | — |
| Research Site | Fort Worth | Texas | 76104 | — |
| Research Site | San Angelo | Texas | 76904 | — |
| Research Site | Tomball | Texas | 77375 | — |
| Research Site | Salt Lake City | Utah | 84124 | — |
| Research Site | West Jordan | Utah | 84088 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03143101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2018 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03143101 live on ClinicalTrials.gov.